AgnistaBio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

AgnistaBio is an early-stage, private AI-driven biotechnology company leveraging its proprietary AgnistaAI platform (comprising AgTa-Pro, AgTa-Ab, and AgTa-cPep modules) to revolutionize drug discovery. The platform aims to predict dynamic, 4D protein-protein interactomes and design developable human antibodies and cyclic peptides against challenging targets like GPCRs and cryptic epitopes. The company is pre-revenue and operates a platform/therapeutics hybrid business model, seeking partnerships and co-development deals with pharmaceutical and biotech firms to advance its pipeline.

Inflammatory DiseasesCancerHeart Failure

Technology Platform

AgnistaAI platform comprising AgTa-Pro (for predicting dynamic 4D protein-protein interactomes), AgTa-Ab (for designing human antibodies against difficult targets like GPCRs and cryptic epitopes), and AgTa-cPep (for designing cyclic peptides). It uses AI to predict structures and interactions from amino acid sequences to accelerate drug discovery.

Opportunities

The company operates in the high-growth AI drug discovery market, with a platform specifically targeting historically undruggable protein classes like GPCRs, which represents a major unmet need and large addressable market for new therapeutics.

Its partnership-focused model allows for capital-efficient validation and revenue generation while building its own asset portfolio.

Risk Factors

Key risks include the need for robust wet-lab validation of its AI predictions, intense competition from other well-funded AI biotech firms, and dependence on securing ongoing funding to advance its technology and pipeline in a challenging financial environment for early-stage companies.

Competitive Landscape

AgnistaBio competes in a crowded and rapidly evolving field of AI-driven drug discovery companies, such as Recursion, Exscientia, and Insilico Medicine, as well as tech giants like Google DeepMind (Isomorphic Labs). Its differentiation claims lie in its specific focus on dynamic 4D interactomes and designing biologics for cryptic epitopes and untargetable proteins.

More companies in AI / Machine Learning →More companies in United States →